What are the fundraising trends in the AI in drug discovery market?
In our AI in drug discovery market deck, you will find everything you need to understand the market
SUMMARY
We analyzed publicly disclosed equity rounds raised by pure-play AI in drug discovery companies across full-year 2024, full-year 2025, and year-to-date 2026 through July. The tracker keeps disclosed rounds of at least $300K, excludes grants, debt, IPOs, clinical-operations tools, diagnostics-only companies, CROs, manufacturing, commercial analytics, and companies where AI-enabled discovery or preclinical candidate selection is not the core business.
The AI in drug discovery market is attracting more headline capital, but the increase is extremely concentrated. Disclosed funding rose from about $1.54B in 2024 to about $1.84B in 2025, and the market had already reached about $2.42B by early July 2026.
The headline capital trend is dominated by a few platform rounds. Xaira represented about 65% of 2024 capital, Isomorphic Labs represented about 33% of 2025 capital, and Isomorphic Labs represented about 87% of year-to-date 2026 capital with its $2.1B Series B.
Deal activity is broadening even while capital concentrates. The number of qualifying deals increased from 16 in 2024 to 28 in 2025, and 19 deals had already been announced by early July 2026, compared with 12 over the comparable period in 2025.
Round-size inequality is the central feature of the AI in drug discovery market. So far in 2026, the average round was about $127M, while the median round was only $10.5M, meaning the average says much more about one mega-round than about what a typical company can raise.
Capital is moving later-stage faster than deal count is. Seed and Series A represented most year-to-date 2026 deals, but Series B and later rounds captured about 88% of capital, almost entirely because of Isomorphic Labs.
De Novo Design is the strongest subcategory by capital momentum. It captured about 73% of 2024 capital, about 61% of 2025 capital, and about 94% of year-to-date 2026 capital, showing persistent investor preference for platforms that claim to create molecules, proteins, antibodies, or other therapeutic matter directly.
AI Lead Generation is gaining breadth, while Preclinical Prediction AI is gaining deal visibility at smaller check sizes. AI Target Discovery remains active but has much lower capital intensity than design-led categories, suggesting target-only stories are harder to fund at platform scale.
Europe leads year-to-date 2026 capital, but mainly because Isomorphic Labs is headquartered there. By deal count, Europe and North America are much closer, with 9 European deals and 8 North American deals so far in 2026.
The AI in drug discovery market is becoming a two-layer financing market: many seed and Series A experiments at the bottom, and a small number of strategic platform winners at the top. The practical read is that investors still want exposure to the category, but the largest checks require proprietary data, experimental feedback loops, drug-program ownership, or elite strategic backing.
This chart, featured in our AI in drug discovery market deck, shows revenue breakdown by customer segment in the AI in drug discovery market
Is more or less capital going into the AI in drug discovery market?
More capital is going into the AI in drug discovery market, but the increase is highly outlier-driven. Full-year disclosed funding rose from about $1.54B in 2024 to about $1.84B in 2025, and year-to-date 2026 funding had already reached about $2.42B by early July, versus about $860M over the comparable period in 2025.
The headline answer is therefore clearly “more capital.” But the honest interpretation is that the AI in drug discovery market is not seeing evenly distributed funding expansion. In 2024, Xaira’s $1B launch round accounted for about 65% of disclosed capital. In 2025, Isomorphic Labs’ $600M external investment accounted for about 33% of full-year capital. In year-to-date 2026, Isomorphic Labs’ $2.1B Series B accounted for about 87% of all disclosed capital.
The cleaner comparison is capital excluding the largest deal. So far in 2026, capital excluding the largest round was about $317M, compared with about $260M over the comparable period in 2025. That still points to growth, but it is a modest increase, not the nearly 3x jump suggested by the headline total.
The AI in drug discovery market is attracting more money, but investors are not spreading that money evenly across the category. The strongest capital signal is that investors are willing to write enormous checks for perceived platform winners, while the ordinary company still raises much smaller rounds.
For the full funding breakdown, see the full AI drug discovery market report.
Is AI in drug discovery funding activity driven by more deals or larger rounds?
AI in drug discovery funding activity is being driven by both more deals and larger outlier rounds, but the capital increase is much more about larger rounds. Deal count increased from 16 disclosed deals in 2024 to 28 in 2025, and the market had 19 deals by early July 2026 compared with 12 over the comparable period in 2025.
That means the AI in drug discovery market is not just one or two companies raising money. More companies are getting funded, and the number of unique funded companies rose from 15 in 2024 to 25 in 2025. The 2026 year-to-date picture also shows broader formation, with 19 unique companies raising by early July.
But the dollar increase is still being driven by round-size concentration. So far in 2026, the market raised about $2.42B, but $2.1B came from Isomorphic Labs alone. Without that one deal, the year-to-date total would be about $317M, which is only modestly higher than the comparable 2025 period once its largest deal is also excluded.
The round-size metrics make the point even clearer. The year-to-date 2026 average round was about $127M, while the median round was only $10.5M. When the average is more than 12x the median, funding activity is not being repriced upward for a typical company; a few companies are simply raising at a completely different scale.
Is AI in drug discovery capital moving toward later-stage or earlier-stage companies?
AI in drug discovery capital is moving decisively toward later-stage companies, even though most deals are still early-stage. In 2024, Seed, Series A, and Unknown rounds captured about 82% of capital. In 2025, Series B and later rounds plus Growth Equity captured about 71% of capital. So far in 2026, Series B and later rounds captured about 88% of capital.
The deal-count picture looks very different. In year-to-date 2026, Seed and Series A represented 16 of 19 deals, or about 84% of deal activity. This means the AI in drug discovery market is still generating many early-stage companies, but the largest checks are no longer going mainly to first financings or new platform launches.
The 2026 shift is especially important because Isomorphic Labs moved from first external financing in 2025 to Series B in 2026. In 2025, Isomorphic made first financings look unusually capital-heavy. In 2026, the same company became the clearest example of capital moving toward a proven winner.
The practical interpretation is that the AI in drug discovery market has become barbell-shaped. Investors still fund many seed and Series A experiments, but the overwhelming majority of dollars are now reserved for companies that look like scale-up infrastructure or validated platform leaders.
This chart, featured in our AI in drug discovery market deck, compares the main business model options for AI drug discovery biotech companies
Is the AI in drug discovery market maturing or still experimental?
The AI in drug discovery market is maturing at the top, but it remains experimental across the long tail. The market is no longer only a set of small AI-biology experiments, because 2025 and 2026 included large platform financings from Isomorphic Labs, Insilico Medicine, Chai Discovery, Enveda, Iambic, Profluent, and other later-stage or growth companies.
At the same time, the typical company still does not look mature. The year-to-date 2026 median round was only $10.5M, while the average was about $127M. The largest round was 200x the median. That is not the shape of a stable, broadly mature financing market.
Category maturity is uneven too. De Novo Design captured about 61% of full-year 2025 capital and about 94% of year-to-date 2026 capital, which shows strong investor conviction in platforms that directly design therapeutic matter. By contrast, Preclinical Prediction AI and AI Target Discovery continue to raise, but mostly at much smaller check sizes.
The best description is selectively institutional. The AI in drug discovery market is mature enough to produce billion-dollar platform financing, but not mature enough for capital to be evenly distributed across stages, categories, geographies, or investors.
Are new startups still entering the AI in drug discovery market?
Yes, new startups are still entering the AI in drug discovery market, and the formation signal is healthy. First financings represented about 31% of 2024 deals, about 36% of 2025 deals, and about 42% of year-to-date 2026 deals.
The freshest signal is especially clear. So far in 2026, 8 of 19 disclosed deals were first financings. Those companies span De Novo Design, AI Target Discovery, AI Lead Optimization, and Preclinical Prediction AI, which means new-company formation is not limited to one subcategory.
But new startups are not capturing the largest pools of capital. First financings represented about 42% of year-to-date 2026 deals but only about 5% of capital. That is a major change from 2024 and 2025, when exceptional company-formation events such as Xaira and Isomorphic made first financings look much larger by dollars.
The practical takeaway is that the AI in drug discovery market remains open to new entrants, but the market is no longer giving new entrants the biggest checks by default. New companies can still raise, but platform-scale capital now requires exceptional credibility, proprietary data, a strong feedback loop, or elite sponsorship.
For a deeper view of startup formation in the category, see the AI drug discovery market deck.
Are more investors entering the AI in drug discovery market?
More investors appear to be participating in the AI in drug discovery market so far in 2026, but the investor base is fragmented rather than tightly organized. The 2026 year-to-date universe includes about 93 disclosed investor names across 19 deals, compared with about 30 disclosed investor names over the comparable period in 2025.
That is a strong breadth signal. The AI in drug discovery market is attracting biotech investors, AI investors, deep-tech investors, sovereign and strategic capital, corporate venture groups, regional funds, and named angels. The category is no longer confined to a narrow set of specialist biotech funds.
But more investor names should not be confused with coordinated conviction. So far in 2026, only a few disclosed investors appeared in more than one deal, including daphni, Y Combinator, Alexandria Venture Investments, i&i Biotech Fund, Kadmos Capital, and Clement Delangue.
The interpretation is that investor participation is widening, but repeat specialization is still thin. Many investors are placing selective bets on specific modalities or founder teams, rather than building broad repeat exposure to the AI in drug discovery market.
This chart, featured in our AI in drug discovery market deck, shows annual funding in AI drug discovery startups
Are top investors getting more or less active in AI in drug discovery?
Top investors are becoming more visible in the largest AI in drug discovery rounds, but they are not necessarily becoming more active across the whole market. The biggest 2026 rounds include elite names such as Thrive Capital, Alphabet, GV, CapitalG, MGX, Temasek, DCVC, NVentures, Bessemer Venture Partners, Andreessen Horowitz, Sutter Hill Ventures, Alexandria Venture Investments, and Dimension Capital.
The difference is selectivity. In 2024, repeat investors included Bpifrance Large Venture, Khosla Ventures, Lux Capital, Wendel, Eurazeo, Elaia, Cathay Innovation, DCVC, Atomico, and WRF Capital. In 2025, the repeat-investor list looked thinner, with names such as General Catalyst, Insight Partners, Lux Capital, Menlo Ventures, and Dimension appearing more than once.
So far in 2026, top-tier investors are highly concentrated in a few rounds rather than spread evenly across the market. Isomorphic Labs has the strongest strategic-capital syndicate. Proxima, Converge Bio, Boltz, Fathom, Tamarind, and 10x Science also show high-quality investor participation, but most of those top investors do not appear repeatedly across the full deal list.
The best interpretation is that top investors are getting more selective, not simply more active. In the AI in drug discovery market, a top-tier investor syndicate should be read as a company-specific credibility signal, not proof that the entire category is uniformly validated.
Which AI in drug discovery subcategories are gaining momentum?
De Novo Design is the AI in drug discovery subcategory gaining the most momentum. It captured about 73% of disclosed capital in 2024, about 61% in 2025, and about 94% in year-to-date 2026, making it the clearest premium category across all three periods.
The De Novo Design signal is not only about one company. The category represented 6 of 16 deals in 2024, 8 of 28 deals in 2025, and 7 of 19 deals so far in 2026. Investors are repeatedly backing companies that claim to create molecules, proteins, antibodies, molecular glues, proximity medicines, or programmable biology systems.
AI Lead Generation is also gaining breadth. Full-year AI Lead Generation capital rose from $180M in 2024 to about $244M in 2025, while deal count rose from 2 to 7. So far in 2026, the category has 4 deals and about $51M, including chemistry, microbial genome mining, simulation, and discovery workflow infrastructure.
Preclinical Prediction AI is gaining deal visibility even though it remains undercapitalized. The category had 1 qualifying deal in 2024, 2 in 2025, and 3 so far in 2026. That suggests toxicity prediction, ADMET, protein characterization, and candidate assessment are becoming recognized discovery bottlenecks, even if investors are not yet pricing them like platform winners.
Which AI in drug discovery subcategories are losing momentum?
AI Target Discovery appears to be losing capital momentum, even though it continues to attract deals. The category had 4 deals and about $121M in 2024, 3 deals and about $53M in 2025, and 4 deals but only about $48M so far in 2026.
That pattern suggests target discovery is not disappearing. The weaker signal is that investors are less willing to fund target discovery alone at platform scale unless the company also has proprietary biological data, a validated target pipeline, or a path into candidate design.
AI Drug Repurposing also looks weak as a broad category. In 2024, the category had one qualifying deal, Healx. In 2025, the category’s two deals were both Enveda. So far in 2026, there are no qualifying AI Drug Repurposing deals in the provided year-to-date universe.
AI Lead Optimization is mixed rather than clearly losing momentum. It grew strongly in 2025, with about $185M across 6 deals, but year-to-date 2026 has only one qualifying deal. Fathom’s $47M Series A shows that serious capital is still available when optimization is tied to physics, quantum chemistry, or small-molecule design, but the category is not getting the same repeated platform premium as De Novo Design.
For the category-by-category funding history, see the market report covering AI drug discovery subcategories.
This chart, featured in our AI in drug discovery market deck, shows how Shrödinger is positioned in AI drug discovery
Which regions are gaining momentum in AI in drug discovery funding?
Europe is gaining the most capital momentum in the AI in drug discovery market, but the capital signal is heavily dependent on Isomorphic Labs. Europe captured about 16% of full-year 2024 capital, about 38% of full-year 2025 capital, and about 89% of year-to-date 2026 capital.
The headline European capital share should be discounted because $2.1B of Europe’s $2.16B year-to-date 2026 total came from Isomorphic Labs. Without that round, Europe would still be active by count, but it would not dominate the market by dollars.
Europe is also gaining deal momentum, which makes the regional story more than a single-round artifact. Europe had 7 deals in 2024, 6 in 2025, and 9 by early July 2026. The 2026 European deal list includes OutSee, Sable Bio, Pharmacelera, Antiverse, Ternary Therapeutics, Generare, DeepCyte, Helical, and Isomorphic Labs.
Asia-Pacific is gaining visibility, but not enough to call it a broad formation hub. Asia-Pacific had no qualifying deals in 2024, 2 deals in 2025, and 2 deals so far in 2026. The region is visible through companies such as Insilico Medicine, ChemLex, Galux, and Peptris, but deal density remains much lower than in North America or Europe.
Which regions are losing momentum in AI in drug discovery funding?
North America is losing momentum only in headline capital share, not in underlying company formation. North America captured about 84% of 2024 capital and about 53% of 2025 capital, but only about 9% of year-to-date 2026 capital.
That apparent decline is mostly caused by Isomorphic Labs’ European $2.1B round. The underlying North American picture is still strong: North America had 8 deals in 2024, 19 deals in 2025, and 8 deals already by early July 2026.
North America also has a higher typical round size in the 2026 year-to-date window. Its median regional round was about $19M, compared with Europe’s $6.5M. That means North America is not weak at the company level; it simply does not own the largest 2026 outlier.
The Middle East has lost visibility in the current year. It had one qualifying deal in 2024, one in 2025, and no qualifying deals so far in 2026. But the sample is too small to call that a structural decline. Latin America and Africa have no qualifying activity in the provided periods, which points to persistent absence rather than recent deterioration.
Is the AI in drug discovery market becoming more global or more regionally concentrated?
The AI in drug discovery market is becoming more global by company formation, but more regionally concentrated by capital. Full-year 2025 included North America, Europe, Asia-Pacific, and the Middle East. Year-to-date 2026 includes North America, Europe, and Asia-Pacific.
Deal count is relatively distributed across the two main hubs. So far in 2026, Europe had 9 deals and North America had 8, with Asia-Pacific adding 2. That is a much more balanced picture than the capital split suggests.
Capital is much more concentrated. Europe captured about 89% of year-to-date 2026 capital, North America captured about 9%, and Asia-Pacific captured about 2%. The capital geography is therefore dominated by one European mega-round, while company formation is much more evenly split between Europe and North America.
The best read is that the AI in drug discovery market is globalizing at the experimentation layer and concentrating at the strategic-capital layer. New companies can emerge in multiple regions, but the largest checks still require exceptional institutional networks, strategic capital, and elite AI-biotech ecosystems.
This chart, featured in our AI in drug discovery market deck, shows how pharma partnerships have driven growth in the AI drug discovery market over time
Is AI in drug discovery capital moving toward proven winners or new opportunities?
AI in drug discovery capital is moving toward proven winners, while deal count still shows strong interest in new opportunities. So far in 2026, first financings represented about 42% of deals but only about 5% of capital.
That is a major change from the prior two years. In 2024, first financings captured about 69% of capital because of Xaira. In 2025, first financings captured about 47% of capital because of Isomorphic Labs’ first external financing. In 2026, Isomorphic became a follow-on Series B, and first-financing capital collapsed as a share of the total.
This does not mean new opportunities are being ignored. Eight first financings by early July 2026 is a healthy startup formation signal. But the biggest capital pools are moving to companies with prior operating history, strategic backing, platform credibility, or stronger evidence that their systems can produce useful discovery outputs.
The AI in drug discovery market has moved from funding the novelty of the platform story to doubling down on platforms that already look validated. The biggest checks now go to perceived winners, while new opportunities mostly receive normal seed and Series A capital.
For a fuller view of repeat raisers and first financings, see the full market view on AI drug discovery funding.
Is the AI in drug discovery market becoming winner-takes-most?
Yes, the AI in drug discovery market is becoming winner-takes-most again in 2026, after looking somewhat more balanced in 2025. In 2024, the top deal captured about 65% of capital and the top 3 deals captured about 77%. In 2025, concentration eased, with the top deal capturing about 33% and the top 3 deals capturing about 48%.
So far in 2026, concentration has surged. The top deal captured about 87% of capital, the top 3 deals captured about 92%, the top 10 deals captured about 98%, and the bottom half of deals captured only about 2%.
The largest-deal-to-median-deal ratio is the cleanest warning sign. The largest year-to-date 2026 round was 200x the median round. That means the AI in drug discovery market is not a smooth funding market; it behaves like a platform tournament where one or two winners can dominate the capital pool.
But the market is not winner-takes-all by deal count. There were 19 funded companies by early July 2026, and most raised far below $50M. The winner-takes-most dynamic applies to dollars, while the company-formation layer remains broad.
Is the next wave of AI in drug discovery winners becoming visible?
Yes, the next wave of AI in drug discovery winners is becoming visible, but financial visibility should not be confused with clinical proof. Isomorphic Labs is already the clearest capital winner, with $600M in 2025 and $2.1B in 2026. Other visible companies include Chai Discovery, Profluent, Enveda, Iambic, Proxima, Fathom, Boltz, Converge Bio, and Excelsior Sciences.
The strongest visibility belongs to companies that connect AI to direct therapeutic creation or high-value bottleneck control. De Novo Design repeatedly captured the largest capital shares across 2024, 2025, and year-to-date 2026. That pattern suggests investors believe the next financial winners are more likely to come from platforms that can design or optimize therapeutic matter than from narrow workflow tools.
There is also an emerging infrastructure layer. Companies such as Tamarind Bio, Helical, Inductive Bio, Sable Bio, DeepCyte, 10x Science, and Fathom Therapeutics suggest that not every winner needs to be an end-to-end drug creator. Some winners may own critical bottlenecks such as model orchestration, target discovery workflows, toxicity prediction, protein characterization, quantum chemistry, or ADMET decision support.
The caveat is important. Funding visibility is not clinical validation. The next wave of financial winners is becoming clearer, but the next wave of therapeutic winners will only be confirmed when these platforms convert funding into validated candidates, partnerships, INDs, clinical assets, or meaningful readouts.
As this chart shows, and as featured in our AI in drug discovery market deck, search interest in AI drug discovery has grown rapidly
Is the AI in drug discovery funding landscape fragmenting or consolidating?
The AI in drug discovery funding landscape is fragmenting by company count and investor participation, while consolidating by capital allocation. Deal count rose from 16 in 2024 to 28 in 2025, and the market already had 19 deals by early July 2026.
Investor participation is also fragmented. So far in 2026, roughly 93 disclosed investor names appeared across 19 deals, but only a small number appeared more than once. That means many investors are placing selective bets rather than forming a tightly repeated syndicate structure.
Capital allocation is moving in the opposite direction. The largest year-to-date 2026 deal captured about 87% of all capital, and the bottom half of deals captured only about 2%. That is consolidation at the dollar layer, even while experimentation is spreading across more companies and subcategories.
The best description is bifurcation. The opportunity set is fragmenting into many specialized approaches, but the capital pool is consolidating around a few perceived platform leaders. For market analysis, deal count and dollar volume now answer very different questions.
Where is investor attention shifting in AI in drug discovery?
Investor attention in the AI in drug discovery market is shifting toward platforms that connect AI outputs to therapeutic creation, experimental validation, and proprietary feedback loops. De Novo Design captured about 61% of full-year 2025 capital and about 94% of year-to-date 2026 capital, which is the clearest category-level evidence.
Investor attention is also shifting toward later-stage platform validation. In 2024, early-stage rounds captured most capital because Xaira was counted as a first financing. In 2025, Series B and later rounds plus Growth Equity captured about 71% of capital. So far in 2026, Series B and later rounds captured about 88% of capital.
There is a quieter shift toward enabling layers. Preclinical Prediction AI remains small by capital, but its deal count is rising. AI Lead Generation is broadening through chemistry automation, molecular data generation, self-driving labs, and synthesis bottleneck companies.
The strongest financing signal now requires at least one of three assets: proprietary biological or chemical data, a closed-loop experimental system, or ownership of drug programs. Companies with generic AI workflow tooling can still raise, but they are less likely to command platform-scale capital.
For deeper analysis of where investor attention is moving, see the deeper analysis of the AI drug discovery market.
INSIGHTS
The insights below come from reviewing disclosed equity rounds in the AI in drug discovery market across full-year 2024, full-year 2025, and year-to-date 2026 through July.
- The AI in drug discovery market is growing, but headline growth is a poor proxy for broad market health. Capital rose from about $1.54B in 2024 to $1.84B in 2025 and about $2.42B by early July 2026, but the largest round represented 65% of 2024 capital and 87% of year-to-date 2026 capital.
- The market’s central feature is asymmetry, not simple acceleration. A year-to-date 2026 median round of $10.5M and average round of about $127M mean the “average company” implied by the funding total does not really exist.
- The largest-deal-to-median-deal ratio moved from 28.6x in 2024 to 13.9x in 2025, then to 200x in year-to-date 2026. The 2025 market looked temporarily more balanced, but 2026 reverted to extreme concentration.
- De Novo Design has become the market’s clearest premium category because it consistently combines high deal share with disproportionate capital share. Investors repeatedly pay more for platforms that claim to create therapeutic matter directly.
- AI Target Discovery is active but structurally under-monetized relative to design categories. The category has maintained deal flow, but its capital share fell from about 8% in 2024 to about 3% in 2025 and about 2% so far in 2026.
- The funding market is implicitly ranking discovery tasks by perceived value capture. Creating molecules, proteins, antibodies, and new therapeutic modalities receives platform-scale funding, while identifying targets or predicting toxicity receives smaller enabling-layer funding.
- The strongest companies are not merely AI companies; they are AI-plus-execution companies. The best-funded examples usually connect models to proprietary data, wet labs, chemistry automation, protein design, therapeutic pipelines, or strategic pharma-grade development capability.
- The market is maturing at the top before it matures in the middle. A few companies can raise hundreds of millions or billions, while many credible seed and Series A companies still raise normal venture-sized rounds.
- First financings remain common, but first-financing capital has collapsed in 2026. First financings represented 42% of year-to-date 2026 deals but only 5% of capital, which means new entrants are plentiful but not yet trusted with very large balance sheets.
- The 2024 and 2025 first-financing capital shares were inflated by exceptional launch events. Xaira and Isomorphic made first financings look more capital-heavy than ordinary new-company formation actually was.
- The AI in drug discovery market is not consolidating by company count. Deal count rose from 16 in 2024 to 28 in 2025 and reached 19 by early July 2026, which points to expanding experimentation.
- The AI in drug discovery market is consolidating by dollars. The top 3 deals captured 77% of 2024 capital, 48% of 2025 capital, and 92% of year-to-date 2026 capital.
- Investor participation is broad but shallow. Roughly 93 disclosed investors appeared in year-to-date 2026, but only a handful showed up more than once, suggesting many investors are testing the category rather than building repeat exposure.
- Europe’s current capital leadership should be discounted as an ecosystem signal because Isomorphic Labs dominates the figure. Europe’s deal count is genuinely strong, but its 89% year-to-date 2026 capital share is mostly one company.
- North America remains the deepest ordinary formation market even when it loses headline capital share. Its year-to-date 2026 median round of about $19M is higher than Europe’s $6.5M median.
- Asia-Pacific is visible but not yet dense. The region has meaningful companies and occasional larger financings, but deal count remains too small to infer a broad financing ecosystem comparable to North America or Europe.
- The most useful diligence filter is whether the company controls a feedback loop. Companies with data generation, wet-lab validation, automated chemistry, or owned programs deserve more weight than companies with only model-access claims.
- Model quality alone is becoming less sufficient as a fundraising narrative. The largest rounds increasingly require model quality plus modality expertise, proprietary data, experimental closure, or a credible path to clinical assets.
- Preclinical Prediction AI may be strategically important despite low capital share. Its rising deal count suggests investors recognize toxicity, ADMET, and candidate assessment as bottlenecks, even if those businesses are not yet priced like dominant platforms.
- AI Lead Generation is becoming broader and more infrastructure-like. The category increasingly includes synthesis, automated chemistry, molecular data generation, and cloud discovery workflows, not just virtual screening.
- The most dangerous analytical mistake is treating all AI drug discovery financings as equivalent. A $5M model-tooling seed round, a $50M chemistry automation round, and a $2.1B platform round measure very different things: experimentation, bottleneck control, and strategic infrastructure conviction.
This chart, featured in our AI in drug discovery market deck, shows how AI drug discovery platform technology has evolved over time
OUR METHODOLOGY TO BUILD THIS TRACKER
We built this AI in drug discovery funding tracker by reviewing publicly disclosed equity rounds raised by pure-play AI in drug discovery companies across full-year 2024, full-year 2025, and year-to-date 2026 through July. A company counts as pure-play when more than 80% of its activity is dedicated to AI-enabled discovery or preclinical candidate selection before human trials.
We define the AI in drug discovery market as AI-enabled software and related services that materially support the identification and design of therapeutic candidates before human trials. We include AI used for target identification and validation, hit and lead generation, lead optimization, de novo design, repurposing, and preclinical prediction or assessment, including ADMET and toxicity. We exclude AI primarily used for clinical trial operations, regulatory submissions, manufacturing, pharmacovigilance, or commercial and enterprise analytics not directly tied to discovery and preclinical candidate selection.
We applied four core filters. First, we only included equity rounds, so grants, debt, structured financings, IPOs, acquisitions, licensing deals, partnerships, and business-combination transactions were excluded. Second, we only counted disclosed rounds of $300K or more. Third, we only kept pure-play companies where AI-enabled discovery or preclinical candidate selection was core to the business. Fourth, every entry had to be confirmed by a direct company announcement, investor announcement, press release, tier-1 media report, specialist industry source, or relevant regional publication.
Undisclosed-amount rounds are excluded from dollar-based metrics because including them would distort funding totals, averages, medians, concentration ratios, and category shares. The 2024 review identified one relevant undisclosed round, Envisagenics’ Series B, which was excluded from quantitative metrics because the amount and $300K threshold could not be verified from the announcement.
All metrics are calculated on the disclosed qualifying sample only. Large outlier rounds are preserved because they are real market signals, but the analysis also uses medians, concentration ratios, totals excluding the largest deal, and totals excluding rounds above $50M to avoid overstating what a typical AI in drug discovery company raises.
Related blog posts
- The latest update in AI for drug discovery
- The latest news in AI for drug discovery
- How large is the AI in drug discovery market in reality?
- The latest funding news in AI for drug discovery
- The evolution of funding activity in AI for drug discovery
- Which companies have raised the most funding in AI for drug discovery?
- Which companies are the most valued in AI for drug discovery?
